Immune Pharmaceuticals Inc. (IMNP) Trading Down 5%
Shares of Immune Pharmaceuticals Inc. (NASDAQ:IMNP) dropped 5% during mid-day trading on Monday . The stock traded as low as $1.08 and last traded at $1.13. Approximately 538,102 shares were traded during mid-day trading, a decline of 11% from the average daily volume of 602,657 shares. The stock had previously closed at $1.19.
The firm’s market capitalization is $11.95 million. The stock’s 50 day moving average is $1.57 and its 200-day moving average is $1.79.
An institutional investor recently raised its position in Immune Pharmaceuticals stock. Susquehanna International Group LLP grew its stake in shares of Immune Pharmaceuticals Inc. (NASDAQ:IMNP) by 41.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 69,805 shares of the biopharmaceutical company’s stock after acquiring an additional 20,488 shares during the quarter. Susquehanna International Group LLP owned about 0.69% of Immune Pharmaceuticals worth $215,000 as of its most recent SEC filing. 4.36% of the stock is owned by institutional investors and hedge funds.
WARNING: “Immune Pharmaceuticals Inc. (IMNP) Trading Down 5%” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/11/immune-pharmaceuticals-inc-imnp-trading-down-5.html.
Immune Pharmaceuticals Company Profile
Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.
Receive News & Stock Ratings for Immune Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.